Skip to main content

Table 2 SUCRA values of treatments for PFS and adverse events

From: Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis

 

Treatment efficacy

 

Treatment

SUCRA

Rank

PFS

 Overall population with ovarian cancer

PARPi

98%

1

Bevacizumab

52%

2

Control

0%

3

 Women with a BRCAm

PARPi

100%

1

Bevacizumab

50%

2

Control

0%

3

 Women with HRD

PARPi

100%

1

Bevacizumab

50%

2

Control

0%

3

Adverse events

 All populations

Control

93%

1

Bevacizumab

57%

2

PARPi

0%

3

  1. BRCAm BRCA1/2 mutation, HRD Homologous-recombination deficiency, SUCRA Surface under the cumulative ranking probabilities
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us